Hidradenitis suppurativa is often described as nothing like acne. At an advanced stage, that’s true, but at the follicular level, the separation is less absolute than we tend to admit. Both conditions begin with follicular instability. What differs is how far things are allowed to progress.

In acne, pathology stays largely within the pilosebaceous unit. In hidradenitis suppurativa, follicles rupture earlier, inflammation amplifies, tissue architecture breaks down and the environment becomes profoundly hypoxic. Once that happens, the microbiology shifts, biofilms organise, and the disease starts to behave more like a chronic inflammatory system than a skin infection.

Reducing bacterial load still helps — especially anaerobic burden — but eradication alone rarely changes trajectory once sinus tracts and immune amplification are established. What does matter is how the follicular environment is modified, how inflammation is modulated, and knowing when topical strategies have reached their ceiling and escalation is biologically necessary.

I’ve written a longer piece exploring how acne and hidradenitis suppurativa sit on the same follicular inflammatory spectrum, why certain acne actives still make sense in early or adjunctive HS care, and where NICE-aligned escalation becomes essential.

EXECUTIVE SUMMARY

Hidradenitis suppurativa and acne are usually positioned as fundamentally different diseases. In advanced disease that distinction is justified, yet both conditions originate from follicular instability occurring within an environment permissive to inflammation.

Acne remains largely confined to the pilosebaceous unit, shaped by sebum composition, keratinisation, oxygen gradients and Cutibacterium acnes behaviour. In hidradenitis suppurativa, follicles rupture earlier and consequences are amplified. Tissue architecture breaks down, oxygen tension falls and lesions evolve into chronic, low-oxygen inflammatory niches.

These environmental changes shift microbiology. Cutibacterium acnes becomes less central, while polymicrobial anaerobic communities resembling chronic wound biology dominate. Antibiotics struggle not because organisms are inherently resistant, but because the environment protects them.

Core follicular actives originally developed for acne remain relevant. Triethyl citrate and oligopeptide-10 deliver meaningful bacterial reduction, including anaerobes and resistant strains, while simultaneously modifying the follicular environment. In acne, bactericidal effects are central to control. In hidradenitis suppurativa, bacterial reduction improves symptoms but is rarely sufficient alone once structural disease and immune amplification are established.

Effective management depends on combining intelligent bacterial reduction with follicular stabilisation, inflammation modulation and timely escalation. Topical strategies have value early, between flares and as adjuncts, but escalation to specialist intervention is essential when disease progresses.

The key message is not eradication versus environment, but understanding how both interact and when biology demands escalation.

Hidradenitis Suppurativa, Acne, and the Follicular Inflammatory Spectrum

Environment, metabolism and immune tone rather than eradication

Hidradenitis suppurativa is usually described as something fundamentally separate from acne, and in its established forms that distinction is justified. The depth of lesions, the degree of scarring and the systemic inflammatory burden clearly set it apart. Yet when you look closely at how both conditions begin, and more importantly how they persist, the separation becomes less absolute. Both are disorders of follicular behaviour occurring within an environment that has become permissive to inflammation.

In acne, that environment is largely confined to the pilosebaceous unit. Sebum composition, follicular keratinisation, oxygen gradients and Cutibacterium acnes behaviour dominate the picture. In hidradenitis suppurativa, the same follicular instability is present, but the consequences are more severe. Follicles rupture more easily, the immune response is exaggerated, tissue architecture breaks down and low-oxygen niches develop that favour anaerobic persistence. What begins as follicular disease evolves into a chronic inflammatory system.

This distinction helps explain why similar primary follicular actives can be relevant across both conditions, while still requiring different adjunctive strategies as disease severity increases.

The original pharmacy formulation now known as Aknicare, and its technologically evolved counterpart in the Tebiskin OSK system, were never conceived as treatments for hidradenitis suppurativa. They were designed to alter follicular conditions in acne: reducing lipid-dependent microbial behaviour, normalising keratinisation and calming inflammatory signalling without resorting to aggressive antimicrobial killing. What became apparent clinically is that these same principles remain relevant as disease extends deeper.

Triethyl citrate remains central to this approach, and its role should not be understated. Microbial behaviour in both acne and hidradenitis suppurativa is closely tied to lipid metabolism, but triethyl citrate does far more than simply starve bacteria of substrate. The local pH shift it produces, down towards the mid-3 range, is not trivial. That degree of acidification directly impairs bacterial enzymatic activity, destabilises membrane integrity and alters transmembrane transport. When combined with oligopeptide-10, which increases bacterial membrane permeability and interferes with adhesion, the result is not merely ecological pressure but active bacterial killing.

In acne, this bactericidal effect is central to efficacy. Rapid and substantial reduction in Cutibacterium acnes load alters porphyrin production, toll-like receptor stimulation and downstream inflammatory signalling. Acne studies demonstrating eradication of the vast majority of C. acnes strains, including macrolide-resistant isolates, make that point very clearly. In this context, bacterial reduction is not incidental; it is one of the primary therapeutic benefits, and one of the reasons alcohol-based delivery systems perform so well when intelligently formulated. Getting actives rapidly beneath the microcomedone matters, because that is where bacterial behaviour and immune signalling intersect.

Where nuance becomes important is not in denying bacterial killing, but in understanding how that same mechanism translates into hidradenitis suppurativa.

Once hidradenitis suppurativa lesions establish — particularly nodules, abscesses and sinus tracts — the environment changes in a way that fundamentally differentiates the condition from acne. Oxygen tension drops, tissue architecture breaks down, and keratin, blood products and inflammatory exudate accumulate. At this point, the pathology is no longer confined to a modified pilosebaceous unit. It has become a chronic, low-oxygen inflammatory niche.

In that environment, Cutibacterium acnes becomes much less central. It may still be detected, particularly early in disease or at the follicular opening, but it is rarely the dominant driver once lesions are established. Instead, hidradenitis suppurativa tends to show a polymicrobial anaerobic profile that more closely resembles chronic wound biology than acne. Organisms such as Prevotella, Porphyromonas, Peptostreptococcus, Finegoldia magna and Anaerococcus species are repeatedly identified. These bacteria are well adapted to hypoxic, protein-rich environments and are capable of persisting within inflamed tissue and organised biofilms. They are not classic skin surface commensals in the way C. acnes is, and many are more commonly associated with mucosal or deep soft-tissue infection.

Staphylococci are also frequently present, including Staphylococcus aureus and coagulase-negative species, but again their role differs from acne. In hidradenitis suppurativa they tend to behave as secondary colonisers, exploiting disrupted tissue rather than initiating disease. Their presence can amplify inflammation, but eliminating them rarely alters the underlying tendency for lesions to recur.

Biofilm behaviour is one of the most important distinctions, and one that is often underappreciated. In acne, biofilm formation by C. acnes is relatively limited and remains follicle-centred. In hidradenitis suppurativa, biofilms are more organised, more persistent and often embedded within sinus tracts and fibrotic tissue. Once this architecture exists, antibiotics struggle — not because the organisms are inherently resistant, but because the environment itself protects them.

This context is essential when considering bacterial reduction strategies. In hidradenitis suppurativa, reducing bacterial burden still matters. Anaerobic organisms contribute to inflammation, tissue damage and malodour, and lowering their load reduces antigenic stimulation and dampens innate immune activation. The ability of the triethyl citrate and oligopeptide-10 combination to penetrate and act in low-oxygen environments gives it a genuine advantage over agents such as benzoyl peroxide, whose mechanisms are oxygen-dependent and therefore poorly suited to deep, hypoxic lesions.

The limitation is not that bacterial killing is unimportant, but that it is rarely sufficient on its own once follicular rupture, sinus formation and immune amplification are established. Killing bacteria improves the environment, but it does not restore follicular integrity or reset an exaggerated immune response that has become self-sustaining. This is why antibiotics can reduce pain and drainage yet fail to prevent recurrence, and why even effective bacterial suppression must be accompanied by strategies that address keratinisation, barrier fragility and inflammatory tone.

Ethyl linoleate addresses one of these vulnerabilities directly. Relative linoleic acid deficiency within follicles alters keratinocyte differentiation and weakens follicular walls. In acne this promotes comedone formation; in hidradenitis suppurativa it increases the likelihood of rupture and exaggerated immune activation. Restoring linoleate locally improves follicular stability and sebum quality, reducing the mechanical failure that initiates inflammation. This is not something antibiotics can achieve, regardless of duration.

Oligopeptide-10 adds a further layer by interfering with persistence rather than growth. Biofilm organisation is a feature of chronic acne lesions, but it becomes a defining problem in hidradenitis suppurativa once sinus tracts and hypoxic tissue are established. By disrupting adhesion and early biofilm integrity, oligopeptide-10 weakens the structures that protect microbes from immune clearance and antibiotics alike. The immune system is exposed to fewer chronic triggers, and inflammatory signalling gradually settles.

The alcohol vehicle used in these formulations deserves explicit recognition rather than apology. In acne, alcohol facilitates rapid penetration into the follicular canal, reduces surface lipid load and delivers actives beneath the microcomedone where C. acnes and its associated inflammatory signals operate. In hidradenitis suppurativa, penetration is even more critical. Actives need to reach unstable follicles and early tracts within low-oxygen tissue. When used intelligently, alcohol is not an irritant but a delivery advantage, allowing high local concentrations where they are biologically relevant. The short-term barrier disruption is offset by a net reduction in inflammatory activity.

Seen this way, the OSK system can be understood as a core follicular environment modifier, applicable across the inflammatory follicular spectrum. What differs in hidradenitis suppurativa is not the relevance of these actives, but the need to address additional layers of immune and systemic amplification.

This is where adjunctive strategies such as Rosagate become important. Hidradenitis suppurativa skin exists in a state of heightened immune reactivity. Neurogenic inflammation, cytokine amplification and barrier fragility lower the threshold for escalation. Rosagate does not replace follicular intervention, nor should it be positioned as a primary treatment. Its role is to reduce inflammatory noise, calm exaggerated signalling and improve tissue tolerance. In practice, this can reduce flare intensity, support healing phases and make the environment less permissive to progression.

Systemic inflammatory load also matters more in hidradenitis suppurativa than in acne, and ignoring it limits outcomes. Supplementation with agents such as MSM and silymarin can be viewed not as disease-specific treatments, but as tools for moderating oxidative stress, inflammatory signalling and hepatic clearance pathways that influence skin behaviour. Their role is supportive rather than curative, but in a condition defined by chronicity, support accumulates.

Dietary and lifestyle factors sit in the same category. Smoking, insulin resistance, mechanical friction and chronic stress do not cause hidradenitis suppurativa, but they raise inflammatory tone and reduce resilience. Addressing them is not about blame or perfection, but about reducing background load so that local interventions have a chance to work.

When these elements are combined — follicular environment modification through OSK-derived actives, inflammation modulation with Rosagate, and reduction of systemic inflammatory burden — hidradenitis suppurativa often becomes quieter. Lesions are less likely to propagate, less likely to escalate, and easier to bring back under control. The disease may not disappear, but its behaviour changes.

That shift in behaviour is the real therapeutic goal. Hidradenitis suppurativa does not respond well to eradication strategies because it is not an infection, but neither does it ignore bacterial burden. It responds best when bacterial load is reduced intelligently, follicular integrity is supported, immune amplification is calmed, and the conditions that favour persistence are progressively removed. The overlap with acne at the follicular level does not diminish the seriousness of hidradenitis suppurativa; it simply reminds us that biology rarely respects the boundaries we draw between diagnoses.

Knowing when topical strategies are no longer enough

Clarity around limitation is as important as confidence in mechanism. Follicular environment modification can meaningfully influence disease behaviour, but it is not a substitute for escalation when disease has moved beyond the reach of local control.

From a NICE-aligned perspective, hidradenitis suppurativa should not be managed indefinitely at a topical level once lesions are recurrent, scarring is evident, or sinus tracts are forming. Continued reliance on repeated antibiotic courses to maintain control is not a marker of success; it is a signal that underlying biology has outgrown the intervention being applied.

OSK-based topical care has a clear role in early disease, in maintenance between flares, and alongside systemic therapies to reduce new lesion formation and limit propagation. It remains valuable as part of combination care, but it should no longer be expected to carry the burden of disease control alone when pain, quality-of-life impact, or structural damage are progressing.

At that stage, escalation is not a failure of topical strategy, but an appropriate response to disease biology. Referral for specialist intervention, including biologic therapy, procedural approaches such as deroofing or laser, or surgical excision in advanced disease, reflects alignment with established care pathways rather than abandonment of earlier principles. Even then, follicular environment modification and inflammation control continue to have a role, but as supporting players rather than anchors.

Recognising when to escalate protects patients from prolonged under-treatment and preserves trust in clinical judgement. It also reinforces the central message of this discussion: effective management of hidradenitis suppurativa depends not on choosing between bacterial reduction and environmental control, but on understanding how both interact, where each has limits, and when structural disease requires decisive intervention.